Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot early signs of rare lung disease

NCT ID NCT07176260

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether the way blood cells work and handle stress can help doctors detect and predict the course of pre-capillary pulmonary hypertension, a serious lung condition. Researchers will collect blood samples from 120 patients during routine visits over three years and compare them with standard heart and lung tests. The goal is to find simple blood markers that could guide personalized care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to help doctors detect and monitor pre-capillary pulmonary hypertension earlier and more accurately.
What could go wrong
This is an observational study, not a treatment trial. It is small (120 patients) and only looks at markers, so it may not lead to a practical test or change in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prevalent or incident patients with pre-capillary pulmonary hypertension

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥18 years) diagnosed with pre-capillary pulmonary hypertension confirmed by right heart catheterization * Patients classified according to the international clinical classification: * Group 1: Pulmonary arterial hypertension (PAH) * Group 3: Pulmonary hypertension associated with chronic respiratory diseases and/or hypoxia * Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) * Patients scheduled for routine clinical follow-up and/or right heart catheterization at the study center. * Ability and willingness to provide informed consent for participation and data analysis. Exclusion Criteria: * Postcapillary pulmonary hypertension (pulmonary arterial wedge pressure \>15 mmHg). * Conditions precluding safe blood sampling (e.g., severe anemia, coagulopathy). * Patients already enrolled in interventional clinical trials that could interfere with mitochondrial or oxidative stress measurements * Patients unable or unwilling to provide informed consent * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic thromboembolic pulmonary hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic thromboembolic pulmonary hypertension pulmonary arterial hypertension pulmonary hypertension pulmonary hypertension owing to lung disease and/or hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-capillary pulmonary hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg - Service Physiologie explorations fonctionnelles

    RECRUITING

    Strasbourg, Bas-Rhin, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.